J 2023

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

STUHEC, Matej, M. HAHN, Ivana TAŠKOVÁ, I. BAYRAKTAR, I. FITZGERALD et. al.

Základní údaje

Originální název

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

Autoři

STUHEC, Matej (705 Slovinsko), M. HAHN (276 Německo), Ivana TAŠKOVÁ (203 Česká republika, domácí), I. BAYRAKTAR (792 Turecko), I. FITZGERALD (372 Irsko), L. MOLITSCHNIG (40 Rakousko), A. TATAREVIC (191 Chorvatsko), N. LINDNER (40 Rakousko), L. AGNOLETTO (40 Rakousko) a F. DA COSTA (620 Portugalsko)

Vydání

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, NETHERLANDS, SPRINGER, 2023, 2210-7703

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.400 v roce 2022

Kód RIV

RIV/00216224:14160/23:00133605

Organizační jednotka

Farmaceutická fakulta

UT WoS

001073897200001

Klíčová slova anglicky

Clinical pharmacist interventions; Clinical pharmacy in mental health; European society of clinical pharmacy; Mental illnesses and pharmacy; Pharmaceutical services in mental health; Polypharmacy and clinical pharmacy; Psychotropics and clinical pharmacy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 28. 2. 2024 07:22, Mgr. Daniela Černá

Anotace

V originále

A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.